/sician:	etor:		Carata	. 5		
hysician: /sician:	ctor:		Contact Phone #: Contact Phone #:			
/sician:						
	Recipient's Physician:			Contact Phone #:		
			Conta	ct Phone #:		
Recipient Name:		DOB:	Hospital ID	#:		
ness or surg	ery:					
sfusion relate	ed fatality? (If Yes	s vou must no	tify FDA within 24	hours)	☐ Yes ☐ No	
		s, you must no	any i Di Wildilli ET			
		e event:				
was irradiate	ed.					
Source	Type of Product	Whole Bloo	od Number/Lot #	Transfusion Start Time/Date	Transfusion Stop Time/Date	
Source	Type of Product	Whole Bloo	od Number/Lot #	Transfusion Start Time/Date		
Source		Whole Bloo	od Number/Lot #			
Source		Whole Blod	od Number/Lot #			
Source		Whole Bloo	od Number/Lot #			
Source		Whole Blod	od Number/Lot #			
Source		Whole Blod	od Number/Lot #			
Source		Whole Block	od Number/Lot #		Transfusion Stop Time/Date	
	ansfusion related ansfusion as ed units of blocks). For TRA	Adverse Event: ansfusion associated adverse ed units of blood, blood composes). For TRALI, only include	sfusion related fatality? (If Yes, you must note Adverse Event: ansfusion associated adverse event:  ed units of blood, blood component, or blood es). For TRALI, only include products transclude all products transclude all products transfused within 3 weeks	sfusion related fatality? (If Yes, you must notify FDA within 24 Adverse Event: ansfusion associated adverse event:  ed units of blood, blood component, or blood derivative adminites). For TRALI, only include products transfused within 6 hour clude all products transfused within 3 weeks of beginning of sy	sfusion related fatality? (If Yes, you must notify FDA within 24 hours)	

Effective Date: see cover sheet

Title: Transfusion Associated Adverse Event Report Number: FRM-0184 Version: 1

Please describe the adverse event:
Please complete for possible TRALI
Are the following present?
Acute onset of respiratory distress? Yes No
Hypoxemia as defined as one of the following?
- PaO2/FIO2<300 mm Hg
<ul> <li>Oxygen saturation &lt;90% on room air  Yes  No If Yes, value:</li> <li>Other clinical evidence (please explain):</li> </ul>
- Other chilical evidence (picase explain).
Bilateral lung infiltration in the chest radiograph?
Possible circulatory overload? Yes No
- Central venous pressure (time):
- History of heart failure/medications?:
Are any of the following present prior to transfusion?
- Sepsis or Septic Shock
- Aspiration
- Pneumonia
- Multiple trauma Yes No Acute pancreatitis Yes No
- Any other acute lung injury or risk factor?
Recipient HLA Class I and II typing has been ordered
Recipient Human Neutrophil Antigen (HNA) has been ordered
- Please attach HLA and HNA reports if available
Note: Recipient HLA Class Land II typing and HNA typing must be known to implicate a donor in TRALL SDRR wi

Version: 1

Effective Date: see cover sheet

Title: Transfusion Associated Adverse Event Report

Number: FRM-0184

Note: Recipient HLA Class I and II typing and HNA typing must be known to implicate a donor in TRALI. SDBB will not routinely test donors for antibodies to HLA or HNA if the transfusion service has not ordered recipient typing. Please contact us with questions concerning testing. SDBB can arrange to send out donor testing in coordination with the transfusion service. The transfusion service will be billed for the costs of recipient testing.

Title: Transfusion Associated Adverse Event Report Number: FRM-0184 Version: 1 Effective Date: see cover sheet

Please complete for suspected BACTERIAL CONTAMINATION
Are the following present?
What are the findings in the recipient?  - Temp pretransfusion Temp posttransfusion  - Temp max 24 hrs prior to transfusion
What are the culture results?
- Patient culture results (site, organism)
- Blood product culture results (time of transfusion, culture, findings)
Was blood product hemolyzed?
Was blood product hemolyzed?
Additional information:
Please complete for Transfusion-Associated Graft vs. Host Disease (GVHD)
Possible TA-GVHD
Is the patient immunocompromised Yes No If yes, please explain:
Did the patient receive non-irradiated cellular blood products within 3 weeks of
symptoms
Were any units directed donations from family members
Did the recipient receive HLA matched platelets within 3 weeks of symptoms
Has the patient had a bone marrow or organ transplant
Please complete for Posttransfusion Purpura (PTP)
Possible PTP
PTP is usually characterized by a dramatic thrombocytopenia 5-10 days following a blood transfusion in a patient with a history of sensitization to platelet specific antigens by pregnancy or transfusion.
Pretransfusion plt ct/date: Lowest Posttransfusion plt ct/date:
History of pregnancy Yes No
Previous history of Neonatal Alloimmune Thrombocytopenia in children
History of previous transfusion
Did the recipient receive HLA matched platelets within 3 weeks of symptoms
Has the patient had a bone marrow or organ transplant
Please explain:
Please attach relevant laboratory values including platelet specific antigens or antibodies.

Mail or Fax to:

Medical Director, San Diego Blood Bank 3636 Gateway Center Ave, Suite 100 San Diego, CA 92102 Fax # 619-220-8416